Palisade Bio Q3 net loss widens to $14.62 million
PALI•Palisade Bio’s third-quarter 2026 net loss widened year over year to $14.62 million, while research and development expenses rose to $10.58 million. The company reported $113.6 million in cash and said its Phase 2b trial dosed its first patient on October 27.
1. Quarterly results and trials
Palisade Bio’s third-quarter 2026 net loss widened year over year to $14.62 million, and research and development expenses rose to $10.58 million, primarily reflecting PALI-2108’s advancement into Phase 2 development and higher employee-related expenses. Cash and cash equivalents totaled $113.6 million at September 30, which the company said is expected to fund operations through key Phase 2 milestones. The Phase 2b ASCENTRA-UC trial dosed its first patient on October 27, with topline results expected in Q4 2027; enrollment in the Phase 2a ASCENTRA-CD trial is targeted for Q1 2027, with a primary efficacy readout expected in Q1 2028.
